A5001228294- Renal cell carcinoma treatment
- Lymphoma Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Chronic Myeloid Leukemia Treatments
- Multiple and Secondary Primary Cancers
- Eosinophilic Disorders and Syndromes
- Colorectal Cancer Treatments and Studies
- SARS-CoV-2 and COVID-19 Research
- Renal and related cancers
- Cutaneous lymphoproliferative disorders research
- Infectious Disease Case Reports and Treatments
- Cancer therapeutics and mechanisms
- Colorectal and Anal Carcinomas
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Hematological disorders and diagnostics
- Heparin-Induced Thrombocytopenia and Thrombosis
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Vaccine Coverage and Hesitancy
Saint Laurent Polyclinique
2025
Université Côte d'Azur
2020
Centre Antoine Lacassagne
2017-2020
Centre Hospitalier Universitaire de Nice
2012-2019
Centre Henri Becquerel
2008-2015
Centre Virchow-Villermé
2008-2015
Université de Rouen Normandie
2015
Centre Hospitalier Universitaire de Rouen
2015
Inserm
2008-2013
La Ligue Contre le Cancer
2012
// Ophélie Cassuto 1 - 4* , Maeva Dufies 2* Arnaud Jacquel 2 Guillaume Robert Clémence Ginet Alix Dubois Amine Hamouda Alexandre Puissant 1,2 ,# Fredéric Luciano Jean-Michel Karsenti 3 Laurence Legros Jill Patrice Pascal Lenain 4 Patrick Auberger C3M/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France Equipe Labellisée Ligue Nationale contre le Cancer 2011-2013, Paris, Service d’Hématologie Clinique et de...
Sunitinib is one of the first-line standard treatments for metastatic clear cell renal carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective discover predictive markers response adapt treatment at diagnosis.Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 setting (SUVEGIL and TORAVA trials). plasmatic level CXCL7 baseline was correlated progression-free survival (PFS).The cut-off...
The t(11;14)(q13;q32) is the hallmark of mantle cell lymphoma (MCL). Additional genetic alterations occur in majority cases. This study aimed to design a polymerase chain reaction (PCR) assay determine incidence and relevance recurrent gene copy number aberrations this disease. Forty-two MCL cases with frozen- or paraffin-embedded (FFPE) tissues were selected. Three different quantitative Multiplex PCR Short Fluorescent Fragments (QMPSF) assays designed simultaneously analyse eight genes...
Abstract Background Dihydropyrimidine dehydrogenase (DPD) status is an indicator of a marked risk for toxicity following fluoropyrimidine (FP)-based chemotherapy. This notion well-established low DPD but little known about the clinical impact high activity. study examined possible link between intrinsic lymphocytic activity and overall survival, progression free survival response to FP-based treatment in patients treated our institution. Methods Lymphocytic was assessed group 136 receiving...
Abstract Background Current international expert guidelines in the 1st line setting for HR+/HER2- ABC recommend endocrine therapy plus a CDK4/6 inhibitor unless there is visceral crisis. However, due to lack of sequencing data, recommendations further treatment lines are not clear-cut. In this context, decisions often based on response first treatment, aggressiveness disease and clinical expertise. Evidence-based medicine should inform decisions. This study aims estimate weight beliefs...
Background: Two thousands teenagers and young adults are diagnosed with cancer in France every year, mostly leukaemia, lymphoma sarcoma. The French National Cancer League has established a “Teenagers & Cancer” program since 2003 the aim of which is to improve medical psychological care for who suffer from cancer. increase this population its specific psycho-social features leads us dedicate an appropriate place environment.
e16557 Background: In the current era of Immune checkpoint inhibitors (ICI), role and timing nephrectomy is still unknown. We aimed to evaluate oncological outcomes patients with metastatic renal cell carcinoma (mRCC) managed for residual disease after complete response (CR) or major partial (mPR defined as > 80%) on sites following ICI. Methods: Patients who underwent prior ICI between 2015 2020 were retrospectively included clinicopathological data reviewed. Perioperative data,...